FDA approves vabomere for complicated UTIs

FDA approves vabomere for complicated UTIs

(HealthDay)—The intravenous antibiotic Vabomere (meropenem and vaborbactam) has been approved by the U.S. Food and Drug Administration to treat certain complicated urinary tract infections, including pyelonephritis.

The drug was evaluated in clinical testing involving 545 adults with complicated urinary tract infections. Some 98 percent of patients treated with Vabomere had a negative urine culture test, compared with 94 percent of those treated with another antibacterial drug, the FDA said in a news release. The most common adverse reactions to Vabomere included headache, allergic-like reactions at the injection site, and diarrhea. Users also may be prone to severe allergic reactions, the agency said.

To lessen the chances of fostering -resistant germs, Vabomere should only be used to treat or prevent infections by susceptible bacteria, the FDA warned.

"The FDA is committed to making new safe and effective antibacterial drugs available," Edward Cox, M.D., director of the Office of Antimicrobial Products in the FDA's Center for Drug Evaluation and Research, said in a statement. "This approval provides an additional treatment option for patients with complicated , a type of serious bacterial ."

Approval for Vabomere was granted to Rempex Pharmaceuticals, based in San Diego.


Explore further

New antibiotic avycaz approved

More information: More Information

Health News Copyright © 2017 HealthDay. All rights reserved.

Citation: FDA approves vabomere for complicated UTIs (2017, August 31) retrieved 23 October 2019 from https://medicalxpress.com/news/2017-08-fda-vabomere-complicated-utis.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.
0 shares

Feedback to editors

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more